Lisinopril-d5 is intended for use as an internal standard for the quantification of lisinopril by GC- or LC-MS. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor (IC50 = 1.2 nM). It reduces the formation of endothelin-1 and increases nitric oxide in human vascular endothelial cells. Lisinopril inhibits the pressor response to angiotensin I in anesthetized rats and dogs (ID50s = 2.3 and 6.5 μg/kg in rat and dog, respectively).
White to Off-White Crystalline Powder
(S)-Lisinopril-d5 is a labeled analogue of (S)-Lisinopril (L468985), an orally active angiotensin-converting enzyme (ACE) inhibitor.
Labelled Lisinopril, intended for use as an internal standard for the quantification of Lisinopril by GC- or LC-mass spectrometry
(S)Lisinopril-D5 can be Labeled , it is an orally active angiotensin-converting enzyme (ACE) inhibitor , intended for use as an internal standard for the quantification of Lisinopril by GC- or LC-mass spectrometry.
[1] A. A. PATCHETT. A new class of angiotensin-converting enzyme inhibitors[J]. Nature, 1980, 288 5788: 280-283. DOI:
10.1038/288280a0[2] GIOVAMBATTISTA DESIDERI. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway.[J]. Mediators of Inflammation, 2008, 2008: 305087. DOI:
10.1155/2008/305087
